Surgery Partners, Inc.

The SGRY CFD: What the Instrument Is and Is Not

A CoinUnited SGRY position is a contract for difference (CFD) that tracks the price of the Nasdaq-listed Surgery Partners, Inc. share. Opening a position provides leveraged price exposure to the stock's market movements. It does not create shareholding, confer voting rights, or entitle the holder to any cash consideration from the pending acquisition.

The amended merger agreement, announced November 9, 2026, provides for HealthSpan Partners to acquire Surgery Partners at $25.00 per share in cash, representing an enterprise value of up to approximately $6.0 billion. That payment, if and when it closes, belongs to registered stockholders of record — not to CFD holders.

The CFD's value derives entirely from the market price of the referenced share as it trades on Nasdaq, and that price is the only input that determines the position's profit or loss.

This distinction is especially important in a contested merger-arbitrage context. As of early November 2026, SGRY was trading above $26.00, pricing in expectations of a competing bid reportedly near $28.00. Surgery Partners' board has chosen to proceed with HealthSpan despite the higher non-binding rival offer, citing closing certainty and regulatory profile.

A CFD holder profits if the spread to any eventual deal price narrows and loses if it widens — whether due to deal-break fears, the rival bid being withdrawn, regulatory complications, or broader market moves. There is no separate legal claim against any deal consideration.

Session Mechanics and Weekend Gap Risk

The SGRY CFD follows a scheduled trading session aligned to the Nasdaq equity market. It is closed at weekends and observes standard US market holidays. The specific session hours and holiday calendar are displayed on the platform before order entry; traders should confirm both before placing or holding positions.

Weekend and holiday gap risk is a particularly concrete consideration for a contested-deal name. Announcements regarding competing bids, board decisions, regulatory rulings, shareholder vote outcomes, financing developments, or deal-break reports can emerge at any time, including outside market hours.

If material news arrives while the market is closed, the stock may open substantially higher or lower than its prior close, with no opportunity to exit in between.

The board's November 9 decision to favour HealthSpan's $25.00 offer over a non-binding $28.00 rival proposal illustrates exactly this dynamic: a headline of that magnitude arriving over a weekend would leave positions exposed to a sharp gap at the open. Positions held through a weekend or holiday carry that gap exposure in full.

Leverage Mechanics: A Worked Example

The maximum leverage available on the SGRY CFD is 1000x, subject to product, jurisdiction, and account eligibility. Leverage amplifies both gains and losses proportionally and can result in liquidation of the full margin deposit.

The arithmetic at 1000x is straightforward but unforgiving:

Step by step: a $50 margin deposit at 1000x controls $50,000 of notional exposure. A 1% adverse move in the underlying share price produces a $500 loss, ten times the margin posted. The position is fully wiped out before the underlying moves 0.1% against it.

For a contested-deal stock, the practical implication is layered. With SGRY trading above $26.00 against a binding offer of $25.00 per share, the market is explicitly pricing in an outcome not yet guaranteed. If the rival bid at $28.00 is formally withdrawn, the stock could retrace sharply toward $25.00 — or lower, if the HealthSpan deal itself faces uncertainty.

That would represent a move well exceeding 1% from current levels, and high leverage magnifies that tail risk proportionally. Traders exploring how M&A dynamics interact with derivatives exposure can find relevant context under the Prop Trading & Retail Derivatives Access Surge theme.

Fee Structure

CoinUnited charges a trading fee on SGRY CFD transactions. The standard tier is not zero-fee. Fees are tiered across nine VIP levels based on 30-day contract volume; the rate declines as volume rises, reaching 0.000% only at VIP 9, which requires 30-day volume of 20,000,000,000 USDT or a qualifying account balance.

The applicable rate for an account's current volume tier is displayed on the platform and listed at coinunited.io/en/account/trading-fees. Traders should confirm their tier rate before calculating net position economics, as fees affect the break-even move required on any leveraged trade.

For a position held to capture a narrow spread between the current market price and any eventual deal consideration, fee cost relative to expected spread capture is a meaningful input — particularly at lower volume tiers where the per-trade rate is higher.

With SGRY trading above the binding $25.00 offer price, the direction and magnitude of the ultimate outcome carry additional uncertainty, making fee-adjusted break-even analysis all the more important before sizing any position.

The broader context for leveraged equity exposure on multi-asset platforms is covered under the TradFi-Crypto Multi-Asset Platform Surge theme.

Surgery Partners operates in the ambulatory surgical center sector, a segment of healthcare delivery that competes with hospital outpatient departments on cost efficiency, physician relationships, payer mix, and case volume.

Structural shifts in surgical site-of-care have consistently favored ASC operators: payers increasingly direct elective and same-day procedures to outpatient settings, where the cost per case is materially lower than in a hospital-based operating room. This dynamic has supported the growth of dedicated ASC platforms as a distinct category within healthcare services.

The $6 Billion Enterprise Value as a Sector Benchmark

The HealthSpan Partners transaction, following a revised offer of $25.00 per share announced in November 2026, now assigns Surgery Partners an enterprise value of approximately $6 billion, inclusive of debt. That figure provides a concrete valuation reference point for the ASC sector at a moment when few pure-play ambulatory surgical operators remain publicly traded.

Equity analysts and sector investors routinely use such transaction multiples to calibrate how remaining public peers are priced relative to private-market clearing levels. With Surgery Partners expected to delist following deal close, that benchmark becomes more significant precisely because the direct comparable disappears from the public market.

For additional context, the earlier Ascension acquisition of AmSurg was valued at $3.9 billion, underscoring how rapidly sector valuations have expanded.

Health System Consolidation and the Bon Secours Mercy Health Rationale

The acquirer's identity is itself a signal about sector direction. HealthSpan Partners is a contractual affiliate and supporting organization of Bon Secours Mercy Health, a large not-for-profit health system. Health systems of this type have pursued ASC partnerships and outright acquisitions as a strategic response to the migration of surgical volume away from hospital campuses.

Capturing ambulatory volume within a health system's network preserves patient relationships and reduces the cost of care delivery, both priorities for not-for-profit systems operating under value-based payment arrangements.

The Surgery Partners transaction fits within a broader pattern of health-sector and multi-industry acquisition activity in which established institutional buyers are acquiring specialized operators to expand their service footprint.

Surgery Partners itself brings more than 200 locations across 30 states, approximately 175 ambulatory surgical centers within a broader footprint exceeding 300 total locations, and roughly 5,000 affiliated physicians to any combined platform.

A Contested Deal: Board Choice and Execution Risk

A significant development emerged in November 2026: HealthSpan raised its offer to $25.00 per share, implying approximately $6 billion in enterprise value, amid reported interest from an unnamed rival that submitted a non-binding proposal near $28.00 per share.

Surgery Partners' board nonetheless selected the HealthSpan offer, citing closing certainty and regulatory profile as decisive factors over headline price. That decision is a material signal about how the board assessed execution risk in the competing proposal.

SGRY's market price of approximately $26.16 as of mid-November 2026 reflects a contested-deal premium above the agreed $25.00 consideration, with the market pricing in some probability that the rival interest resurfaces or that HealthSpan is compelled to improve its terms further.

Bain Capital, which holds approximately 39% of Surgery Partners and agreed to roll over its shares, remains a significant stakeholder whose posture will influence any further negotiation.

Narrowing the Public ASC Peer Group

Surgery Partners' expected delisting reduces the set of publicly traded ASC operators available as direct comparables.

For equity analysts covering the remaining public players, a smaller peer group creates two practical effects: relative valuation multiples may re-rate as the composition of the reference set changes, and the scarcity of direct comparables can widen the dispersion of analyst price targets.

Investors in remaining public ASC operators may find that takeout speculation becomes a more prominent valuation input as the sector's public market shrinks.

Price Discovery After the Merger Agreement

For traders holding SGRY exposure, including via a CFD position that tracks the underlying equity, the most important analytical point is that price discovery is now governed by the merger dynamics rather than by operating performance metrics.

The stock's trading range is currently anchored above the $25.00 revised cash consideration, and movements relative to that level primarily reflect deal-completion probability and contested-bid scenarios rather than fundamental comparisons with sector peers.

Leveraged long positions above $25.00 carry meaningful downside if rival interest is formally withdrawn and the market re-anchors to the agreed price. The transaction is expected to close in the first quarter of 2027, subject to shareholder and regulatory approvals.

Peer analysis remains relevant in one specific context: assessing whether a competing bid is plausible. A competing bidder would need to argue that Surgery Partners is undervalued relative to what the sector commands in the private market, and the approximately $6 billion enterprise value now provides the revised baseline for that argument.

Outside of that scenario, relative-value trading against ASC peers is not the operative framework once a definitive merger agreement is in place.

Traders evaluating the broader M&A environment around this transaction can find sector-level context in the 2026 Stocks Market Outlook, which covers the interest-rate and capital-markets conditions influencing leveraged buyout activity across healthcare services.

With an amended merger agreement now in place following a contested bidding process, Surgery Partners trades as a complex merger-arbitrage instrument.

The price dynamics are no longer driven by operating earnings surprises or sector rotation — they are driven by the market's probability-weighted assessment of deal completion, timeline, the competing-bid situation, and the cost of capital over the holding period.

The Arb Spread as a Price Signal

The amended cash consideration of $25.00 per share represents the floor established by the HealthSpan Partners agreement, implying a transaction enterprise value of up to approximately $6.0 billion. The amendment itself was triggered by an unsolicited competing proposal reportedly at $28.00 per share on a non-binding basis.

With SGRY trading around $26.16 as of early November 2026, the market is pricing in a contested-deal premium above the $25.00 floor — a meaningfully different arb structure than a single-bidder situation.

The gap between the current market price and $25.00 reflects several embedded components:

The current structure is unusual: SGRY's market price exceeds the signed $25.00 consideration, meaning buyers at current levels are explicitly betting on either a higher competing offer or an improved HealthSpan bid.

Surgery Partners' board has already signalled its posture by choosing HealthSpan over the $28.00 non-binding rival, citing closing certainty and regulatory profile — a significant disclosure about the board's view of execution risk in the competing proposal.

Carry costs remain a real input. Capital committed to an arb position has an opportunity cost against prevailing risk-free rates, and elevated implied volatility further raises the spread cushion demanded by arb participants before they commit capital.

Key Upside Catalysts

Three events would compress the spread or push the stock higher:

1. Competing bid formalised above $25.00: If the unnamed rival converts its non-binding $28.00 proposal into a definitive offer, the reference ceiling for SGRY rises materially. The board's rejection of this proposal on execution grounds does not permanently close the door if the rival satisfies due-diligence and regulatory concerns.
2. Regulatory clearance: Antitrust review of healthcare consolidation has been active in recent years. A clean HSR clearance removes the most cited structural risk and compresses the timeline spread.
3. Shareholder vote approval: With Bain Capital affiliates holding approximately 39% of outstanding shares and rolling equity rather than voting against the deal, the practical vote hurdle for the remaining shareholders is lower than a straight majority calculation might suggest.

The October 2026 disclosure of BCPE Seminole Holdings II acquiring a 22.96% stake adds a further governance consideration worth monitoring.

Bain's decision to roll equity remains structurally significant. It signals that the largest single shareholder expects the private entity to retain or create value post-close, and reduces the cash outflow required from HealthSpan Partners at closing, which may marginally reduce financing risk.

Key Downside Risks

Five risk factors can push the stock below $25.00, or well below it if the deal breaks:

1. Rival bid withdrawn, stock reprices to $25.00 floor: SGRY trading above $25.00 creates a unique near-term risk. If the competing proposal is formally withdrawn and no higher HealthSpan offer emerges, the stock would likely fall toward the signed consideration, producing a loss for anyone who entered above that level.
2. Deal termination: If either party exercises a termination right, the stock reverts to a standalone valuation reflecting Surgery Partners' operating fundamentals — not the $25.00 floor. That gap can be substantial given the premium embedded in the signed deal.
3. Operating deterioration triggering MAC clause: Q3 2026 results showed revenue declining 0.8% year over year to $815.3 million and adjusted EBITDA falling to $132.7 million from $136.4 million in Q3 2025.

Same-facility revenue grew 6.0% and revenue per case rose 5.8% to $5,125, but the Idaho Falls hospital divestiture to Intermountain Health in September 2026 complicates consolidated comparisons. If pre-close results weaken further, an acquirer may seek to invoke a material adverse change clause.

1. Antitrust challenge: Healthcare sector M&A has faced heightened regulatory scrutiny. A second-request or extended review would extend the timeline and increase carry costs, particularly relevant if the competing bidder's regulatory profile was a material reason the board declined its proposal.
2. Financing deterioration: The transaction enterprise value of up to approximately $6.0 billion includes debt financing. A material rise in credit spreads or a lender withdrawal before closing can pressure deal economics.

Traders monitoring how rate and yield dynamics interact with M&A pricing can find broader context in the Fed Yield Surge Cross-Asset Repricing theme, which covers the relationship between Treasury yields and risk-asset valuations.

The Multi-Sector M&A Deal Surge theme provides comparable context on deal flow and arb conditions across sectors in the current environment.

CoinUnited CFD Mechanics in an Arb Context

A CoinUnited CFD on SGRY provides price exposure that tracks the underlying equity. It does not confer shareholding or voting rights. Traders take a directional position on whether the stock converges toward $25.00, rises toward the competing-bid level, or falls sharply on deal-risk repricing.

Trading follows a scheduled session and is closed at weekends and on market holidays; the session hours and holiday calendar are shown on the platform before any position is opened.

This matters specifically in merger-arbitrage contexts because catalysts such as regulatory decisions, board announcements, and shareholder votes typically occur on specific dates during market hours — but the stock's response to weekend news will gap at the next open, and that gap risk is real and should be factored into position sizing.

Fees are not zero at the standard tier. CoinUnited uses a tiered structure based on 30-day contract volume across nine VIP levels, reaching 0.000% only at VIP 9; the full schedule is at coinunited.io/en/account/trading-fees.

For arb positions held over weeks, the cumulative fee across entry and exit is a real component of net return alongside carry cost — both should be calculated before sizing a position.

The maximum leverage available on the SGRY CFD is 1000x, subject to product, jurisdiction, and account eligibility. Leverage amplifies both gains and losses and can trigger liquidation before a catalyst resolves.

The contested-deal structure makes this especially relevant: a trader long above $25.00 is exposed not only to the standard deal-termination downside but to the additional drop from current levels to the signed consideration if the competing bid disappears. A worked example illustrates the asymmetry: a $50 margin position at 1000x controls $50,000 of notional exposure.

A 1% adverse move in the underlying produces a $500 loss against a $50 margin balance, which would exceed the margin and trigger liquidation well before any spread resolves. Position sizing in contested merger-arbitrage CFD contexts requires explicit account of this dynamic.